Skip to main content
SpringerLink
Log in

Comparison of Different Doses of Escitalopram in the Prophylaxis of Dementia in Patients with Depression and Moderate Cognitive Dysfunction in Chronic Cerebral Ischemia

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Objective – to compare different doses of escitalopram (Cipralex) in the prophylaxis of dementia in patients with depression and moderate cognitive dysfunction on the background of chronic cerebral ischemia. Materials and methods. Two groups of patients, aged 65–78 years, with chronic cerebral ischemia and mild-moderate depression and moderate cognitive dysfunction were studied and treated with different doses of escitalopram: 30 patients received escitalopram at a dose of 5 mg/day throughout the treatment period; 42 patients received escitalopram at a dose of 5 mg/day for the fi rst week and then 10 mg/day. Treatment duration was six months and the observation period was eight months. Results and conclusions. Escitalopram was shown to be effective not only in the treatment of depression-associated cognitive dysfunction in patients with chronic cerebral ischemia but also in decreasing the risk of dementia in the long term. The effectiveness of the prophylaxis of dementia was found to depend on the escitalopram dose used.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. R. G. Troxler, E. A. Sprague, R. A. Albanese, et al., “The association of elevated plasma cortisol and early atherosclerosis as demonstrated by coronary angiography,” Atherosclerosis, 26, 151–162 (1977); doi: 10.1016/0021-9150(77)90098-3.

    Article  CAS  PubMed  Google Scholar 

  2. R. M. Carney, J. A. Blumenthal, P. K. Stein, et al., “Depression, heart rate variability, and acute myocardial infarction,” Circulation, 104, 2024–2028 (2001); doi: 10.1161/hc4201.097834.

    Article  CAS  PubMed  Google Scholar 

  3. P. L. Morris, R. G. Robinson, P. Andrzejewski, et al., “Association of depression with 10-year poststroke mortality,” Am. J. Psychiatry, 150, 124–129 (1993); doi: 10.1176/ajp.150.1.124.

    Article  CAS  PubMed  Google Scholar 

  4. J. H. Lichtman, E. S. Froelicher, J. A. Blumenthal, et al., “Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: A scientific statement from the American Heart Association,” Circulation, 129, No. 12, 1350–1369 (2014); doi: 10.1161/CIR.0000000000000019.

  5. G. S. Alexopoulos, B. S. Meyers, R. C. Young, et al., “Vascular depression hypothesis,” Arch. Gen. Psychiatry, 54, 915–922 (1997); doi: 10.1001/archpsyc.1997.01830220033006.

    Article  CAS  PubMed  Google Scholar 

  6. M. May, P. McCarron, S. Stansfeld, et al., “Does psychological distress predict the risk of ischemic stroke and transient ischemic attack? The Caerphilly Study,” Stroke, 33, 7–12 (2002); doi: 10.1161/hs0102.100529.

    Article  PubMed  Google Scholar 

  7. S. L. Larson, P. L. Owens, D. Ford, and W. Eaton, “Depressive disorder, dysthymia, and risk of stroke. Thirteen-year follow-up from the Baltimore Epidemiological Catchment Area Study,” Stroke, 32, 1979–1983 (2001); doi: http://dx.doi.org/10.1161/hs0901.094623.

  8. M. C. Pascoe, S. G. Crewther, L. M. Carey, and D. P. Crewther, “Inflammation and depression: why poststroke depression may be the norm and not exception,” Int. J. Stroke, 6, No. 2, 128–135 (2011); doi: http://dx.doi.org/10.1111/j.1747-4949.2010.00565.

  9. A. Singh, S. E. Black, N. Nerrmann, et al., “Functional and neuroanatomic correlations in poststroke depression: The Sunnybrook Stroke Study,” Stroke, 31, 637–644 (2000); doi: http://dx.doi.org/10.1161/01.str.31.3.637.

  10. R. G. Robinson, K. L. Kubos, L. B. Starr, et al., “Mood disorders in stroke patients. Importance of location of lesion,” Brain, 107, 81–93 (1984); doi: http://dx.doi.org/10.1093/brain/107.1.81.

  11. S. H. Lee, M. E. Payne, D. C. Steffens, et al., “Subcortical lesion severity and orbitofrontal cortex volume in geriatric depression,” Biol. Psychiatry, 54, 529–533 (2003); doi: 10.1016/s0006-3223(03) 00063-5.

  12. J. R. MacFall, M. E. Payne, J. E. Provenzale, and K. R. Krishnan, “Medial orbital frontal lesions in late-onset depression,” Biol. Psychiatry, 49, 803–806 (2001); doi: http://dx.doi.org/10.1016/s0006- 3223(00)01113-6.

  13. S. M. MacHale, S. J. O’Rourke, J. M. Wardlaw, and M. S. Dennis, “Depression and its relation to lesion location after stroke,” J Neurol. Neurosurg. Psychiatry, 64, 371–374 (1998); doi: http://dx.doi.org/10.1136/jnnp.64.3.371.

  14. K. Shimoda and R. G. Robinson, “The relationship between poststroke depression and lesion location in long-term follow-up,” Biol. Psychiatry, 45, 187–192 (1999); doi: 10.1016/s0006-3223(98) 00178-4.

  15. D. Sinyor, P. Jacques, D. G. Kaloupek, et al., “Poststroke depression and lesion location: An attempted replication,” Brain, 109, 537–546 (1986); doi: 10.1093/brain/109.3.537.

    Article  PubMed  Google Scholar 

  16. R. Vataja, T. Pohjasvaara, A. Leppävuori, et al., “Magnetic resonance imaging correlates of depression after ischemic stroke,” Arch. Gen. Psychiatry, 58, 925–931 (2001); doi: 10.1001/archpsyc.58.10.925.

    Article  CAS  PubMed  Google Scholar 

  17. A. Berg, H. Palomäki M. Lehtihalmes, et al., “Poststroke depression: An 18-month follow-up,” Stroke, 34, 138–143 (2003); doi: 10.1161/01.str.0000048149.84268.07.

    Article  PubMed  Google Scholar 

  18. G. Gianotti, A. Azzoni, F. Gasparini, et al., “Relation of lesion location to verbal and nonverbal mood measures in stroke patients,” Stroke, 28, 2145–2149 (1997); doi: 10.1161/01.str.28.11.2145.

    Article  Google Scholar 

  19. A. House, M. Dennis, C. Warlow, et al., “Mood disorders after stroke and their relation to lesion location: A CT scan study,” Brain, 113, 1113–1129 (1990); doi: 10.1093/brain/113.4.1113.

    Article  PubMed  Google Scholar 

  20. M. Åström, R. Adolfsson, and K. Asplund, “Major depression in stroke patients: A 3-year longitudinal study,” Stroke, 24, 976–982 (1993); doi: 10.1161/01.str.24.7.976.

    Article  PubMed  Google Scholar 

  21. D. Dam, H. E. Pedersen, and P. Ahlgren, “Depression among patients with stroke,” Acta Psychiatr. Scand., 80, 118–124 (1989).

    Article  CAS  PubMed  Google Scholar 

  22. B. S. Greenwald, E. Kramer-Ginsberg, and K. R. R. Krishnan, “Neuroanatomic localization of magnetic resonance imaging signal hyperintensities in geriatric depression,” Stroke, 29, 613–617 (1998); doi: 10.1161/01.str.29.3.613.

    Article  CAS  PubMed  Google Scholar 

  23. G. M. S. Nys, M. J. E. van Zandvoort, H. B. der Worp, et al., “Early depression symptoms after stroke: Neuropsychological correlates and lesion characteristics,” J. Neurol. Sci., 228, 27–33 (2005); doi: 10.1016/j.jns.2004.09.031.

    Article  CAS  PubMed  Google Scholar 

  24. F. Piamarta, S. Iurlaro, V. Isella, et al., “Unconventional affective symptoms and executive functions after stroke in the elderly,” Arch. Gerontol. Geriat., 9, Supplement, 315–323 (2004); doi: 10.1016/j.archger.2004.04.042.

  25. S. E. Starkstein, J. P. Fedoroff, T. R. Price, et al., “Apathy following cerebrovascular lesions,” Stroke, 24, 1625–1630 (1993); doi: 10.1161/01.str.24.11.1625.

    Article  CAS  PubMed  Google Scholar 

  26. S. Yamagata, S. Yamaguchi, and S. Kovayashi, “Impaired novelty processing in apathy after subcortical stroke,” Stroke, 35, 1935–1940 (2004); doi: 10.1161/01.str.0000135017.51144.c9.

    Article  PubMed  Google Scholar 

  27. K. P. Bhatia, and C. D. Marsden, “The behavioural and motor consequences of focal lesions of the basal ganglia in man,” Brain, 117, 859–876 (1994); doi: 10.1093/brain/117.4.859.

    Article  PubMed  Google Scholar 

  28. R. Levy and B. Dubois, “Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits,” Cereb. Cortex, 16, 916–928 (2006); doi: 10.1093/cercor/bhj043.

    Article  PubMed  Google Scholar 

  29. F. Holsboer, “Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy,” J. Affect. Disord., 62, 77–91 (2001); doi: 10.1016/s0165-0327(00)00352-9.

    Article  CAS  PubMed  Google Scholar 

  30. F. Holsboer, “Corticotropin-releasing hormone modulations and depression,” Curr. Opin. Investig. Drugs, 4, 46–50 (2003).

    CAS  PubMed  Google Scholar 

  31. J. M. Reul and F. Holsboer, “Corticotropin-releasing factor receptions 1 and 2 in anxiety and depression,” Curr. Opin. Pharmacol., 2, 23–33 (2002)l doi: 10.1016/S1471-4892(01)00117-5.

  32. R. M. Sapolsky, “Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders,” Arch. Gen. Psychiatry, 57, 925–935 (2000); doi: 10.1001/archpsyc.57.10.925.

    Article  CAS  PubMed  Google Scholar 

  33. E. Fuchs and E. Gould, “Mini-review: in vivo neurogenesis in the adult brain: regulation and functional implications,” Eur. J. Neurosci., 12, 12211–2214 (2000); doi: 10.1046/j.1460-9568.2000. 00130.x.

  34. M. A. Smith, S. Makino, R. Kvetnansky, and R. M. Post, “Effects of stress on neurotrophic factor expression in the rat brain,” Ann. NY Acad. Sci., 771, 234–239 (1995); doi: 10.1111/j.1749-6632.1995. tb44684.x.

  35. M. Nibuya, S. Morinobu, and S. Duman, “Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments,” J. Neurosci., 15, 7639–7547 (1995).

    Google Scholar 

  36. B. Chen, D. Dowlatshahi, G. M. MacQueen, et al., “Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication,” Biol. Psychiatry, 50, 260–265 (2001); doi: 10.1016/s0006-3223(01)01083-6.

    Article  CAS  PubMed  Google Scholar 

  37. Y. I. Sheline, P. W. Wang, M. H. Gado, et al., “Hippocampal atrophy in recurrent major depression,” Proc. Natl. Acad. Sci. USA, 93, No. 9, 3908–3913 (1996); doi: 10.1073/pnas.93.9.3908.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Y. I. Sheline, M. Sanghavi, M. I. Mintun, and M. H. Gado, “Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression,” J. Neurosci., 19, No. 12, 5034–5043 (1999).

    CAS  PubMed  Google Scholar 

  39. Y. I. Sheline, M. H. Gado, and H. C. Kraemer, “Untreated depression and hippocampal volume loss,” Am. J. Psychiatry, 160, No. 8, 1516–1518 (2003); doi: 10.1176/appi.ajp.160.8.1516.

    Article  PubMed  Google Scholar 

  40. Y. I. Sheline, M. H. Gado, and J. L. Price, “Amygdala core nuclei volumes are decreased in recurrent major depression,” Neuroreport, 8, No. 9, 2023–2028 (1998).

  41. J. D. Bremner, M. Vithilingham, E. Vermetten, et al., “Reduced volume of orbitofrontal cortex in major depression,” Biol. Psychiatry, 51, 273–279 (2002); doi: 10.1016/s0006-3223(01)01336-1.

    Article  PubMed  Google Scholar 

  42. C. E. Coffey, W. E. Wilkinson, R. D. Weiner, et al., “Quantitative cerebral anatomy in depression: a controlled magnetic resonance imaging study,” Arch. Gen. Psychiatry, 50, 7–16 (1993); doi: 10.1001/archpsyc.1993.01820130009002.

    Article  CAS  PubMed  Google Scholar 

  43. T. Lai, M. E. Payne, C. E. Byrum, et al., “Reduction of orbital frontal cortex volume in geriatric depression,” Biol. Psychiatry, 48, No. 10, 971–975 (2000); doi: 10.1016/s0006-3223(00)01042-8.

    Article  CAS  PubMed  Google Scholar 

  44. T. N. van den Kommer, H. C. Comijs, M. A. Aartsen, et al., “Depression and cognition: how do they interrelate in old age?” Am. J. Geriatr. Psychiatry, 21, No. 4, 398–410 (2013); doi: 10.1016/j.jagp.2012.12.01.

    Article  PubMed  Google Scholar 

  45. B. S. Diniz, M. A. Butters, S. M. Albert, et al., “Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies,” Br. J. Psychiatry, 202, No. 5, 329–335, (2013); doi: 10.1192/bjp.bp.112.118307.

    Article  PubMed  PubMed Central  Google Scholar 

  46. J. Altman and G. D. Das, “Autoradiographic and histologic evidence of postnatal neurogenesis in rats,” J. Comp. Neurol., 124, 319–335 (1965); doi: 10.1002/cne.901240303.

    Article  CAS  PubMed  Google Scholar 

  47. M. A. Kheirbek and R. Hen, “(Radio)active neurogenesis in the human hippocampus,” Cell, 153, No. 6, 1183–1184 (2013); doi: 10.1016/j.cell.2013.05.033.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. G. S. Alexopoulos, C. F. Murphy, F. M. Gunning-Dixon, et al., “Serotonin transporter polymorphisms, microstructural white matter abnormalities and remission of geriatric depression,” J. Affect. Disord., 119, No. 1–3, 132–141 (2009); doi: 10.1016/j.jad.2009.03.004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. M. Boldrini, M. D. Underwood, R. Hen, et al., “Antidepressants increase neural progenitor cells in the human hippocampus,” Neuropsychopharmacology, 34, No. 11, 2376–2389 (2009); doi: 10.1038/npp.2009.75.

  50. S. Bleakley, “Review of the choice and use of antidepressant drugs,” Prog. in Neurol. Psychiatry, 17, No. 6, 18–26 (2013); doi: 10.1002/pnp.311.

    Article  Google Scholar 

  51. I. M. Anderson, I. N. Ferrier, R. C. Baldwin, et al., “Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines,” J. Psychopharm., 22, 343–396 (2008); doi: 10.1177/0269881107088441.

    Article  CAS  Google Scholar 

  52. National Institute for Health and Care Excellence, Depression in Adults. Clinical Guideline CG90, NICE, (2009), http://guidance.nice.org.uk/CG90, acces. May 15, 2015.

  53. I. Herrera-Guzmán, E. Gudayol-Ferré, J. E. Herrera-Abarca, et al., “Major depressive disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with major depressive disorder in recovery,” J. Affect. Disord., 123, No. 1–3, 341–350 (2010); doi: 10.1016/j.jad.2009.10.0.

    Article  PubMed  Google Scholar 

  54. G. B. Cassano, F. Puca, P. L. Scapicchio, and M. Trabucchi, Italian Study Group on Depression in Elderly Patients, “Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients,” J. Clin. Psychiatry, 63, No. 5, 396–402 (2002); doi: 10.4088/jcp.v63n0504.

    Article  CAS  PubMed  Google Scholar 

  55. E. L. Constant, S. Adam, B. Gillain, et al., “Effects of sertraline on depressive symptoms and attentional and executive functions in major depression,” Depress. Anxiety, 21, No. 2, 78–89 (2005); doi: 10.1002/da.20060.

    Article  CAS  PubMed  Google Scholar 

  56. C. Katona, T. Hansen, and C. K. Olsen, “A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder,” Int. Clin. Psychopharmacol., 27, No. 4, 215–223 (2012); doi: 10.1097/yic.0b013e3283542457.

    Article  PubMed  Google Scholar 

  57. N. Ishikawa and K. Hashimoto, “The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases,” J. Recept. Lig. Chann. Res., 3, 25–36 (2010); doi: 10.2147/JRLCR.S8453.

    CAS  Google Scholar 

  58. I. Ishima, Y. Fujita, and K. Hashimoto, “Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells,” Eur. J. Pharmacol., 727, 167–173 (2014); doi: 10.1016/j.ejphar.2014.01.064.

    Article  CAS  PubMed  Google Scholar 

  59. R. G. Robinson, R. E. Jorge, D. J. Moser, et al., “Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial,” JAMA, 299, No. 20, 2391–2400 (2008); doi: 10.1001/jama.299.20.2391.

  60. A. Rasmussen, M. Lunde, D. L. Poulsen, et al., “A double-blind placebo-controlled study of sertraline in prevention of depression in stroke patients,” Psychosomatics, 44, 216–222 (2003); doi: 10.1176/appi.psy.44.3.216.

    Article  CAS  PubMed  Google Scholar 

  61. K. Narushima, J. T. Kosier, and R. G. Robinson, “Preventing of poststroke depression. A 12-week double-blind randomized treatment trial with 21-month follow-up,” J. Nerv. Ment. Dis., 190, 296–303 (2002); doi: 10.1097/00005053-200205000-00005.

    Article  PubMed  Google Scholar 

  62. S. Mohamed, K. Osatuke, M. Aslam, and J. Kasckow, “Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial,” Am. J. Geriatr. Pharmacother., 4, No. 3, 201–209 (2006); doi: 10.1016/j.amjopharm.2006.08.001.

    Article  CAS  PubMed  Google Scholar 

  63. S. Kasper, O. M. Lemming, and H. de Swart, “Escitalopram in the long-term treatment of major depressive disorder in elderly patients,” Neuropsychobiology, 54, 152–159 (2006); doi: 10.1159/000098650.

    Article  CAS  PubMed  Google Scholar 

  64. E. Savaskan, S. E. Müller, A. Böhringer, et al., “Antidepressive therapy with escitalopram improves mood, cognitive symptoms, and identity memory for angry faces in elderly depressed patients,” Int. J. Neuropsychopharmacol., 11, No. 3, 381–288 (2008), doi: 10.1017/s1461145707007997.

    Article  CAS  PubMed  Google Scholar 

  65. H.-J. Möller, J. Schnitker, and W. Flürenbrock, “Factors associated with response in depressed elderly outpatients treated with escitalopram in a naturalistic setting in Germany,” Pharmacopsychiatry, 43, 210–215 (2010); doi: 10.1055/s-0030-1254152.

    Article  PubMed  Google Scholar 

  66. R. C. Petersen and J. C. Morris, “Clinical features,” in: Mild Cognitive Impairment: Aging to Alzheimer’s Disease, Oxford University Press, New York (2003), pp. 15–40; doi: 10.1056/nejm 200310023491425.

Download references

Author information

Authors and Affiliations

  1. Interregional Clinical Diagnostic Center, Kazan, Russia

    Yu. V. Zhitkova

Authors
  1. Yu. V. Zhitkova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yu. V. Zhitkova.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 115, No. 8, Iss. 1, pp. 53–60, August, 2015.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhitkova, Y.V. Comparison of Different Doses of Escitalopram in the Prophylaxis of Dementia in Patients with Depression and Moderate Cognitive Dysfunction in Chronic Cerebral Ischemia. Neurosci Behav Physi 47, 296–302 (2017). https://doi.org/10.1007/s11055-017-0396-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-017-0396-0

Search

Navigation